Canaccord Genuity reissued their buy rating on shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) in a research note published on Sunday morning, Marketbeat Ratings reports. The firm currently has a $44.00 price target on the stock, down from their previous price target of $48.00.

A number of other research analysts have also commented on PCRX. ValuEngine raised Pacira Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, June 20th. Wedbush reissued an outperform rating and set a $87.00 target price on shares of Pacira Pharmaceuticals in a report on Wednesday, June 21st. Royal Bank Of Canada set a $58.00 target price on Pacira Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, June 27th. BidaskClub raised shares of Pacira Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, July 5th. Finally, Cowen and Company reissued a hold rating on shares of Pacira Pharmaceuticals in a research report on Friday, July 14th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $52.62.

Pacira Pharmaceuticals (NASDAQ PCRX) opened at 37.45 on Friday. Pacira Pharmaceuticals has a 12-month low of $29.95 and a 12-month high of $58.95. The company’s market capitalization is $1.51 billion. The stock’s 50 day moving average is $37.03 and its 200-day moving average is $43.51.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.06). The firm had revenue of $70.90 million for the quarter, compared to the consensus estimate of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. Pacira Pharmaceuticals’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the business posted $0.21 EPS. On average, equities analysts predict that Pacira Pharmaceuticals will post ($0.17) earnings per share for the current fiscal year.

WARNING: This report was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/04/canaccord-genuity-reaffirms-buy-rating-for-pacira-pharmaceuticals-inc-pcrx.html.

In other news, CAO Kristen Marie Williams sold 3,461 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total transaction of $127,191.75. Following the completion of the transaction, the chief accounting officer now owns 21,312 shares of the company’s stock, valued at approximately $783,216. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $36.37, for a total value of $1,050,547.45. Following the sale, the chief executive officer now owns 159,164 shares of the company’s stock, valued at $5,788,794.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,390 shares of company stock worth $1,215,480. Company insiders own 6.60% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Oppenheimer Asset Management Inc. bought a new position in Pacira Pharmaceuticals in the second quarter valued at about $114,000. Benjamin F. Edwards & Company Inc. raised its stake in Pacira Pharmaceuticals by 12.2% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock worth $133,000 after acquiring an additional 303 shares in the last quarter. FNY Partners Fund LP acquired a new position in Pacira Pharmaceuticals during the first quarter worth about $136,000. Ameritas Investment Partners Inc. acquired a new position in Pacira Pharmaceuticals during the first quarter worth about $144,000. Finally, Cubist Systematic Strategies LLC raised its stake in Pacira Pharmaceuticals by 121.5% during the second quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock worth $152,000 after acquiring an additional 1,752 shares in the last quarter.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.